p.163 抽出テキスト

256. 日本循環器学会,日本不整脈心電学会.2020年改訂版 不整脈薬物治療ガイドライン.https://www.j-circ.or.jp/cms/wp-content/ uploads/2020/01/JCS2020_Ono.pdf 257. Hiramori S, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism. J Cardiol 2022; 80: 487-494. PMID: 35882615 258. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415. PMID: 23991658 259. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510. PMID: 21128814 260. Büller HR, Prins MH, Lensin AW, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297. PMID: 22449293 261. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808. PMID: 23808982 262. Yamashita Y, Morimoto T, Toyota T, et al. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis. Thromb Res 2018; 166: 37-42. PMID: 29655001 263. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371. PMID: 30002145 264. Nakamura M, Wang YQ, Wang C, et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. J Thromb Haemost 2015; 13: 1606-1614. PMID: 26179767 265. Nakamura M, Yamada N, Asamura T, et al. Safety and effectiveness of edoxaban in Japanese venous thromboembolism patients Final analysis of one-year follow-up data from a Japanese postmarketing observational study (ETNA-VTE-Japan). Circ Rep 2020; 2: 192- 202. PMID: 33693227 266. Yamada N, Hirayama A, Maeda H, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism the J-EINSTEIN DVT and PE program. Thromb J 2015; 13: 2. PMID: 25717286 267. Fukuda I, Hirayama A, Kawasugi K, et al. Safety profile and effectiveness of rivaroxaban for patients with venous thromboembolism in Japan Results from post-marketing surveillance (XASSENT). Circ J 2023; 87: 1175-1184. PMID: 37245989 268. Okumura Y, Fukuda I, Nakamura M, et al. J’xactly Investigators. A multicenter prospective observational cohort study to investigate the effectiveness and safety of rivaroxaban in Japanese venous thromboembolism patients (The J'xactly Study). Circ J 2020; 84: 1912- 1921. PMID: 32981924 269. Nakamura M, Nishikawa M, Komuro I, et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circ J 2015; 79: 1230-1236. PMID: 25912695 270. Yamada N, Mo M, Ohsawa A, et al. Safety and effectiveness of apixaban in Japanese patients with venous thromboembolism in clinical practice A post-marketing surveillance. Circ J 2021; 85: 2201-2207. PMID: 33994408 271. Kauppila A. The use of oestrogens and progestin and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589-93. Pharmacol Res 1995; 32: 327. PMID: 8736481 272. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901- 907. PMID: 10089183 273. Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334: 674. PMID: 17289685 274. Agnelli G, Prandoni P, Becattini C, et al. Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25. PMID: 12834314 275. Couturaud F, Sanchez O, Pernod G, et al. PADIS-PE Investigators. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. JAMA 2015; 314: 31-40. PMID: 26151264 276. Fukamachi D, Okumura Y, Fukuda I, et al. J’xactly Investigators.

Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: subanal- ysis of J'xactly. Curr Med Res Opin 2022; 38: 1059-1068. PMID: 35502571 277. Ogino Y, Ishigami T, Minamimoto Y, et al. Direct oral anticoagulant

therapy for cancer-associated venous thromboembolism in routine clinical practice. Circ J 2020; 84: 1330-1338. PMID: 32624519 278. Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967. PMID: 22621626 279. Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979-1987. PMID: 23121403 280. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-1716. PMID: 20975016 281. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4: 4693-4738. PMID: 33007077 282. Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 2016; 6: e011190. PMID: 27154483 283. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205. PMID: 17296569 284. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774. PMID: 10737276 285. Takahashi K, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Age and long-term outcomes of patients with venous thromboembolism: From the COMMAND VTE Registry. Int J Cardiol 2023; 383: 89-95. PMID: 37156304 286. McRae S, Tran H, Schulman S, et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 371-378. PMID: 16876665 287. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813. PMID: 21349898 288. Yoshikawa Y, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Sex differences in clinical characteristics and outcomes of patients with venous thromboembolism From the COMMAND VTE Registry. Circ J 2019; 83: 1581-1589. PMID: 31142685 289. Kaneda K, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Influence of low body weight on long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE registry. Thromb Res 2021; 198: 26-33. PMID: 33264736 290. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011; 342: d3036. PMID: 21610040 291. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8: 2436-2442. PMID: 20723032 292. Schulman S, Wåhlander K, Lundström T, et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-1721. PMID: 14585939 293. Palareti G, Cosmi B, Legnani C, et al. DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 2014; 124: 196-203. PMID: 24879813 294. Kaneda K, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry-2 Investigators. Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. Eur J Intern Med 2023; 118: 59-72. PMID: 37574348 295. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900. PMID: 14644891 296. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban,